Allergan’s agreement to buy San Francisco’s Tobira Therapeutics for as much as $1.7 billion sent biotech stocks soaring Tuesday, as investors bet that buyers will emerge for other companies developing experimental treatments for a severe liver disease. Even biotech giant Gilead Sciences of Foster City, which has treatments for the disease, got a boost...